Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Cash from Operations over the past 12 years, most recently at 23754000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 23754000.0 for Q4 2025, up 67.61% from a year ago — trailing twelve months through Dec 2025 was 276391000.0 (down 18.97% YoY), and the annual figure for FY2025 was 276391000.0, down 18.97%.
  • Cash from Operations for Q4 2025 was 23754000.0 at Viridian Therapeutics, Inc.\DE, up from 84611000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for VRDN hit a ceiling of 11539000.0 in Q1 2021 and a floor of 92653000.0 in Q1 2025.
  • Median Cash from Operations over the past 5 years was 38491500.0 (2023), compared with a mean of 42064950.0.
  • Biggest five-year swings in Cash from Operations: plummeted 194.52% in 2023 and later surged 67.61% in 2025.
  • Viridian Therapeutics, Inc.\DE's Cash from Operations stood at 16535000.0 in 2021, then tumbled by 105.88% to 34042000.0 in 2022, then decreased by 11.63% to 38000000.0 in 2023, then crashed by 92.98% to 73332000.0 in 2024, then surged by 67.61% to 23754000.0 in 2025.
  • The last three reported values for Cash from Operations were 23754000.0 (Q4 2025), 84611000.0 (Q3 2025), and 75373000.0 (Q2 2025) per Business Quant data.